---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-004208"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2022-03-24T23:59:59+00:00"
generated_at: "2026-06-26T18:39:04.330251+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# HOOKIPA reports FY2021 net loss of $75.7M; pro-forma cash $156.9M extends runway to H1 2024

## Summary
- Net loss widened to $75.7M in FY2021 from $44.1M in FY2020; R&D expenses rose to $82.9M.
- Pro-forma cash of $156.9M (Dec 31, 2021) reflects $35M Gilead equity, $15M fee, and $70M follow-on proceeds.
- Gilead HIV program advanced, triggering $54M commitment; $4M milestone, $15M fee, $35M equity at premium.
- HB-200 Phase 2 combo with pembrolizumab in HNSCC dosed Jan 2022; initial data expected H2 2022.
- Klaus Orlinger promoted to CSO; executive team accepted 50% of 2021 bonus in options at $3/share.

## SEC filing metadata
- accession: 0001558370-22-004208
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2022-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000155837022004208/0001558370-22-004208-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000155837022004208/hook-20220324x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-004208
- JSON: https://secwatch.observer/filing/0001558370-22-004208.json
- Plain text: https://secwatch.observer/filing/0001558370-22-004208.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.